Rebecca Pedersini
Overview
Explore the profile of Rebecca Pedersini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moretti L, Richelmi L, Cosentini D, Pedersini R, Grisanti S, Amoroso V, et al.
Breast
. 2024 Nov;
78:103826.
PMID: 39509862
The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to...
2.
Pedersini R, Schivardi G, Lagana M, Laini L, di Mauro P, Zamparini M, et al.
Breast
. 2024 Sep;
78:103794.
PMID: 39265313
Purpose: The impact of dietary counseling on body composition in early breast cancer patients (EBC) treated with aromatase inhibitors (AIs) is uncertain. The aim of this study was to assess...
3.
Blancas I, Grosjean J, Pedersini R, Buzzoni C, Sleilaty G, Molero A, et al.
Future Oncol
. 2024 Aug;
20(31):2371-2384.
PMID: 39115881
This real-world study aimed to describe patient and clinical characteristics, treatment patterns and outcomes for patients with HR+/HER2- metastatic breast cancer receiving abemaciclib in France, Italy and Spain. A multicenter...
4.
Birtolo M, Pedersini R, Palermo A, Vena W, Morenghi E, Cristofolini G, et al.
Eur J Endocrinol
. 2024 Jul;
191(2):117-125.
PMID: 39056237
Background: Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs is still unknown. Methods: This retrospective...
5.
Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, et al.
Clin Breast Cancer
. 2024 May;
24(5):411-420.
PMID: 38734491
Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with...
6.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2024 Feb;
10(1):13.
PMID: 38316819
No abstract available.
7.
Cosentini D, Pedersini R, di Mauro P, Zamparini M, Schivardi G, Rinaudo L, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2350950.
PMID: 38198137
Importance: Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment with bone-active drugs. Risk factors for fractures in patients receiving AIs and...
8.
Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, et al.
Ther Adv Med Oncol
. 2023 Dec;
15:17588359231204857.
PMID: 38130467
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2- aBC). Objectives: While CDK4/6i are known...
9.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2023 Oct;
9(1):89.
PMID: 37903774
No abstract available.
10.
Pedersini R, Lagana M, Bosio S, Zanini B, Cosentini D, di Mauro P, et al.
Breast Cancer Res Treat
. 2023 Sep;
202(3):461-471.
PMID: 37695400
Purpose: We aimed to investigate the role of a lifestyle intervention and clinical and therapeutic factors for preventing weight gain in early breast cancer (BC) patients from one week before...